BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/8/2026 9:34:54 AM | Browse: 9 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca2+/cAMP signaling activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ai Huang, Yang Cao, Bin Li, Jun Xiao, Su-Dong Zhan, Ning-Yu Wang, Xiang-Ping Mei, Si-Zhe Zhao, Jun Han, Yong Xiao, Lin-Fang Wang and Hong Ma |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| China Health & Medical Development Foundation |
chmdf2024-xrzx04-07 |
| Chinese Society of Clinical Oncology |
Y-SY201901-0014 |
|
| Corresponding Author |
Hong Ma, Chief Physician, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430022, Hubei Province, China. wudajianzhu2004@163.com |
| Key Words |
Biliary tract cancer; Surufatinib; Radiosensitivity; GINS4; Ca2+/cAMP signaling pathway |
| Core Tip |
Surufatinib has been approved for the treatment of advanced cholangiocarcinoma. Our clinical trial demonstrates that surufatinib exerts prominent radiosensitizing effects. Its synergistic anti-tumor activity with radiotherapy is mainly achieved by suppressing the expression of GINS4, a critical proliferation-related gene, while simultaneously triggering the activation of Ca2+/cAMP signal cascades. Such molecular changes amplify radiation-triggered DNA injury, aggravate irreversible cellular damage, and ultimately facilitate robust apoptotic death of tumor cells upon radiation exposure. Our study provides more therapeutic options for clinical treatment. |
| Citation |
Huang A, Cao Y, Li B, Xiao J, Zhan SD, Wang NY, Mei XP, Zhao SZ, Han J, Xiao Y, Wang LF, Ma H. Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca2+/cAMP signaling activation. World J Gastroenterol 2026; In press
|
| PDF |
121690-in-press.pdf
|
 |
Received |
|
2026-04-01 03:45 |
|
Peer-Review Started |
|
2026-04-01 03:45 |
|
First Decision by Editorial Office Director |
|
2026-04-29 08:54 |
|
Return for Revision |
|
2026-04-29 08:54 |
|
Revised |
|
2026-05-15 16:45 |
|
Publication Fee Transferred |
|
2026-05-22 11:30 |
|
Second Decision by Editor |
|
2026-09-08 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-09-08 09:34 |
|
Articles in Press |
|
2026-09-08 09:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
